Description of 3 Cases in Vietnam of Aspirin Desensitization in Patients With Coronary Artery Disease and Coexisting Aspirin Hypersensitivity

Abstract

Aspirin (ASA) hypersensitivity comprises types I to III (Cox-1 mediated) and types IV and V (IgE antibody mediated). Rapid, low-dose (81-325 mg/day) ASA desensitization regimens are known to be useful in establishing ASA tolerance in patients with coronary artery disease and coexisting ASA/nonsteroidal anti-inflammatory drug hypersensitivity. We document 3 cases in Vietnam of desensitization to ASA in patients with coronary artery disease and coexisting ASA hypersensitivity. One of these 3 patients had probable immune-mediated hypersensitivity, whereas the remaining 2 had probable Cox-1-mediated reactions. The regimen of desensitization we employed for each patient was designed to account for the probable mechanism of hypersensitivity in the individual and further modified according to the degree of tolerance observed, with all 3 patients eventually achieving a daily cardioprotective dosage of ASA.

ASA Allergy and Desensitization Protocols in the Management of CAD: A Review of Literature

“…The features of different proposed protocols are displayed in Table 1 [23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42].…”